Enhanced dopamine uptake in the striatum following repeated restraint stress

Synapse

Volumn 57, Issue 3, 2005, Pages 167-174

  Copeland, Benjamin J ^a   Neff, Norton H ^a   Hadjiconstantinou, Maria ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b 5034 Graves Hall ^*  (United States)

Author keywords

Corticosterone; Dopamine D2 receptors; Dopamine transporter; Mazindol binding

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; GLUCOCORTICOID RECEPTOR ANTAGONIST; HALOPERIDOL; HOMOVANILLIC ACID; MAZINDOL; MESSENGER RNA; MIFEPRISTONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; IMMOBILIZATION STRESS; KINETICS; MALE; MESENCEPHALON; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; SYNAPTOSOME;

3,4-DIHYDROXYPHENYLACETIC ACID; ADRENALECTOMY; ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC AMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; CORTICOSTERONE; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; ELECTROCHEMISTRY; HALOPERIDOL; HORMONE ANTAGONISTS; MALE; MAZINDOL; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MIFEPRISTONE; NERVE TISSUE PROTEINS; PROTEIN BINDING; QUINPIROLE; RESTRAINT, PHYSICAL; RNA, MESSENGER; STRESS; TIME FACTORS; TRITIUM; TYROSINE;

EID: 22544479093     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20169     Document Type: Article

References (65)

1. Abercrombie ED, Keefe KA, DiFrischia DS, Zigmond MJ. 1989. Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens and medial prefrontal cortex. J Neurochem 52:655-1658.
2. 3H]GBR 12935 binding after chronic treatment with dopamine active drugs. Psychopharmacology 102:291-294.
3. Amara SG, Sonders MS. 1998. Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend 51:87-96.
4. Barrot M, Abrous DN, Marinelli M, Rouge-Pont M, Le Moal M, Piazza PV. 2001. Influence of glucocorticoids on dopaminergic transmission in the rat dorsolateral striatum. Eur J Neurosci 13:812-818.
5. Batchelor M, Schenk OJ. 1998. Protein kinase A activity may kinetically upregulate the striatal transporter for dopamine. J Neurosci 18:10304-10309.
6. Cabib S, Puglisi-Allegra S. 1996a. Different effects of repeated stressful experiences on mesocortical and mesolimbic dopamine metabolism. Neuroscience 73:375-380.
7. Cabib S, Puglisi-Allegra S. 1996b. Stress, depression and the mesolimbic dopamine system. Psychopharmacology 128:331-342.
8. Cabib S, Kempf E, Schleef C, Oliverio A, Puglisi-Allegra S. 1988. Effects of immobilization stress on dopamine and its metabolites in different brain areas of the mouse: role of genotype and stress duration. Brain Res 441:153-160.
9. Cass WA, Gerhardt GA. 1994. Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake. Neurosci Lett 176:259-263.
10. Chi K, Reith MEA. 2003. Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. J Phar Exp Ther 307:729-736.
11. Cho S, Duchemin A-M, Neff NH, Hadjiconstantinou M. 1999. Tyrosine hydroxylase, aromatic L-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs. Brain Res 830:237-245.
12. Claustre Y, Rivy JP, Dennis T, Scatton B. 1986. Pharmacological studies on stress-induced increase in frontal cortical dopamine metabolism in the rat. J Pharmacol Exp Ther 238:693-700.
13. Cohen J, Hadjiconstantinou M, Neff H. 1983. Activation of dopamine-containing amacrine cells of retina: light-induced increase of acidic dopamine metabolites. Brain Res 260:125-127.
14. Copeland BJ, Vogelsberg V, Neff NH, Hadjiconstantinou M. 1996. Protein kinase C activators decrease dopamine uptake into striatal synaptosomes. J Pharmacol Exp Ther 277:1527-1532.
15. Deutch AY, Roth RH. 1990. The determinants of stress-induced activation of prefrontal cortical dopamine system. Prog Brain Res 85:367-402.
16. Dickinson SD, Sabeti J, Larson GA, Giardina K, Rubinstein M, Kelly MA, Grandy DK, Low MJ, Gerhardt GA, Zahniser NR. 1999. Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J Neurochem 72:148-156.
17. Dunn AJ. 1988. Stress-related activation of cerebral dopaminergic systems. Ann NY Acad Sci 537:188-205.
18. Dunn AJ, File SE. 1983. Cold restraint alters dopamine metabolism in frontal cortex, nucleus accumbens and neostriatum. Physiology and Behavior 31:511-513.
19. Figlewicz DP, Patterson TA, Zavosh A, Brot MD, Roitman M, Szot P. 1999. Neurotransmitter transporters: target for endocrine regulation. Horm Metab Res 5:335-339.
20. Fleckenstein AE, Metzger RR, Wilkinss ML, Gibb JW, Hanson GR. 1997. Rapid and reversible effects of methamphetamine on dopamine transporter. J Pharmacol Exp Ther 282:834-838.
21. Gilad GM, Rabey JM, Gilad VH. 1987. Presynaptic effects of glucocorticoids on dopaminergic and cholinergic function in synaptosomes. Implications for rapid endocrine-neural interactions in striatum. Life Sci 40:2401-2408.
22. Goettl VM, Wemlinger TA, Duchemin A-M, Neff NH, Hadjiconstantinou M. 1999. GM1 ganglioside restores dopaminergic neurochemichal and morphological markers in aged rats. Neuroscience 92:991-1000.
23. Gordon I, Weizman R, Rehavi M. 1996. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 298:27-30.
24. Gulley JM, Doolen S, Zahnister NR. 2002. Brief repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. J Neurochem 83:400-411.
25. Hadjiconstantinou M, Neff NH. 1988. Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mouse. J Neurochem 51:1190-1196.
26. Herman JP, Guillonneau D, Dantzer R, Scatton B, Semerdijian-Rouquier L, Le Moal M. 1982. Differential effects of inescapable footshock and of stimuli previously paired with inescapable footshock on dopamine turnover in cortical and limbic areas of the rat. Life Sci 30:2207-2214.
27. 3H]mazindol binding sites in rat striatum by dopaminergic agents. Eur J Pharmacol 250:261-266.
28. Imperato A, Puglisi-Allegra S, Casolini P, Angelucci L. 1991. Changes in dopamine and acetylcholine release during and following stress are independent of the pituitary-adrenocortical axis. Brain Res 538:111-117.
29. Imperato A, Angelucci L, Casolini P, Zocchi A, Puglisi-Allegra S. 1992. Repeated stressful experiences differently affect limbic dopamine release during and following stress. Brain Res 577:194-199.
30. Imperato A, Cabib S, Puglisi-Allegra S. 1993. Repeated stressful experiences differently affect the time-dependent responses of mesolimbic dopamine system to stress. Brain Res 601:333-336.
31. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. 1985a. Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173-2177.
32. 3H]mazindol autoradiography. J Neurosci 5:1513-1521.
33. Keller RW, Stricker EM, Zigmod MJ. 1983. Environmental stimuli but not homeostatic challenges produce apparent increases in dopaminergic activity in striatum: an analysis by in vivo voltametry. Brain Res 279:159-170.
34. Kimmel HT, Joyce AR, Carroll FI, Kuhar MJ. 2001. Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat. J Pharmacol Exp Ther 298:129-140.
35. Kimmel HT, Carroll FL, Kuhar MJ. 2003. Withdrawal from repeated cocaine alters dopamine transporter protein turnover in the rat striatum. J Pharmacol Exp Ther 304:15-21.
36. Kuhar MJ, Pilotte NS. 1996. Neurochemical changes in cocaine withdrawal. Trends Pharmacol Sci 17:260-264.
37. Lamensdorf I, Porat S, Simantov R, Finberg JPM. 1999. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Br J Pharmacol 126:997-1002.
38. Letchworth SR, Sexton T, Childers SR, Vrana KE, Vaughan RA, Davies HML, Porrino LJ. 1999. Regulation of rat dopamine transporter mRNA and protein by chronic cocaine administration. J Neurochem 73:1982-1989.
39. Lindley SE, Bengoechea TG, Schatzberg AF, Wong DL. 1999. Glucocorticoid effects on mesotelencephalic dopamine neurotransmission. Neuropsychopharmacology 21:399-407.
40. Lucas LR, Pompei P, Ono J, McEwen BS. 1998. Effects of adrenal steroids on basal ganglia neuropeptide mRNA and tyrosine hydroxylase radioimmunoreactive levels in the adrenalectomized rat. J Neurochem 71:833-843.
41. Marinelli M, Piazza PV. 2002. Interaction between glucocorticoid hormones, stress and psychostimulant drugs. Eur J Neurosci 16:387-394.
42. Marshall JF, Navarrete RJ. 1990. Contrasting tissue factors predict heterogeneous striatal dopamine neurotoxicity after MPTP or methamphetamine treatment. Brain Res 534:348-351.
43. Mash CD, Pablo J, Ouyang Q, Hearn WL, Izenwasser S. 2002. Dopamine transport function is elevated in cocaine users. J Neurochem 81:292-300.
44. Meiergerd SM, Patterson TA, Schenk JO. 1993. D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem 61:764-767.
45. Metzger RR, Haughey HM, Wilkins DG, Gibb JW, Hanson G, Fleckenstein AE. 2000. Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther 295:1077-1085.
46. Miller GW, Gainetdinov RR, Levey AI, Caron MG. 1999. Dopamine transporters and neuronal injury. Trends Pharmacol Sci 20:424-429.
47. Mortensen OV, Amara SG. 2003. Dynamic regulation of the dopamine transporter. Eur J Pharmacol 479:159-170.
48. Page G, Peeters M, Maloteaux J-M, Hermans E. 2000. Increased dopamine uptake in striatal synaptosomes after treatment of rats with amantadine. Eur J Pharmacol 403:75-80.
49. Parsons LH, Schad CA, Justice JB Jr. 1993. Co-administration of the D2 antagonist pimozide inhibits up-regulation of dopamine release and uptake by repeated cocaine. J Neurochem 60:376-379.
50. Petrie EC, Veith RC, Szot P 1998. Bupropion and desipramine increase dopamine transporter mRNA expression in the ventral tegmental area/substantia nigra of rat brain. Prog Neuropsychopharmacol Biol Psychiatry 22:845-856.
51. Puglisi-Allegra S, Imperato A, Angelucci L, Cabib S. 1991. Acute stress induces time-dependent responses in dopamine mesolimbic system. Brain Res 554:217-222.
52. Rivest R, Falardeau P, Di Paolo T. 1995. Brain dopamine transporter: gender difference and effect of chronic haloperidol. Brain Res 692:269-272.
53. Roth KA, Mefford IM, Barchas JD. 1982. Epinephrine, norepinephrine, dopamine and serotonin: differential effects of acute and chronic stress on regional brain amines. Brain Res 239:417-424.
54. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE. 2001. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci 21:1413-1419.
55. Sarnyai Z, McKittrick CR, McEwen BS, Kreek ML. 1998. Selective regulation of dopamine transporter binding in the shell of nucleus accumbens by adrenalectomy and corticosterone-replacement. Synapse 30:334-337.
56. Saunders C, Ferrer JV, Shi L, Chen J, Merril G, Lamb ME, Leeblunberg LMF, Carvelli L, Javitch JA, Galli A. 2000. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 97:6850-6855.
57. Shilling PD, Kelsoe JR, Segal DS. 1997. Dopamine transporter mRNA is up-regulated in the substantia nigra and the ventral tegmental area of amphetamine-sensitized rats. Neurosci Lett 236:131-134.
58. Slotnick BM, Leonard CM. 1975. A stereotaxic atlas of the albino mouse forebrain. DHEW Publication No. (ADM) 75-100. U.S. Department of Health, Education, and Welfare Public Health Service. Alcohol, Drug Abuse, and Mental Health Administration, Rockville, MD.
59. Tanganelli S, Fuxe K, von Euler G, Eneroth P, Agnati LF, Ungerstedt U. 1990. Changes in pituitary-adrenal activity affect apomorphine-and cholecystokinin-8-induced changes in striatal dopamine release using microdialysis. J Neural Transm Gen Sect 81:183-194.
60. Tatsumi M, Groshan K, Blakely RD, Richleson E. 1997. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249-258.
61. Tecott LH, Kwong LL, Uhr S, Peroutka SJ. 1986. Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine and pimozide. Biol Psychiatry 21:1114-1122.
62. Vermetten E, Bremner JD. 2002. Circuits and systems in stress. I. Preclinical studies. Depress Anxiety 15:126-147.
63. Wiener JM, Hashim A, Lajtha A, Sershen H. 1989. Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier. Eur J Pharmacol 163:191-194.
64. --dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol Ther 92:21-55.
65. Zapata A, Shippenberg TS. 2002. D3 receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens. J Neurochem 81:1035-1042.